|Bid||145.50 x 100|
|Ask||248.84 x 100|
|Day's Range||143.57 - 148.51|
|52 Week Range||36.68 - 192.94|
|PE Ratio (TTM)||-18.15|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about ...
The next generation of breast and ovarian cancer treatment is attacking the deadly disease from all angles. That is no more evident than in the glut of pharmaceutical companies racing to develop, test, ...
Has the market overestimated the odds of success for Tesaro's fancy new cancer drug?